Published in TB and Outbreaks Week, September 16th, 2003
"The prevention of vancomycin-resistant Enterococcus (VRE) colonization and infection continues to be a high priority for clinicians," scientists in the United States explained. "An oral antimicrobial agent that reduces or eliminates VRE gastrointestinal colonization could be useful for preventing VRE infection in selected patients."
"Ramoplanin, a glycolipodepsipeptide, is the first in a new class of antimicrobials," according to M.A. Montecalvo and colleagues at New York Medical College. "It has excellent in vitro activity against vancomycin-resistant...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.